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DETERMINATION OF A DIFFERENTIAL PROTEIN PROFILE IN THE
SYNOVIAL FLUID OF PATIENTS WITH RHEUMATOID ARTHRITIS AND
OSTEOARTHRITIS
J. Mateos, P. Ferna´ndez-Puente, V. Calamia, L. Lourido, C. Ferna´ndez-
Lo´pez, N. Oreiro, C. Ruiz-Romero, F.J. Blanco. Osteoarticular and Aging Res.
Lab., Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A
Corun˜a, Spain
Purpose: Early detection of a biomarker – or a panel of biomarkers –
related to the arthritic processes would be of capital importance not
only for the prediction of the pathology, but also for its handling, the
developing of trials of treatment and, of course, a deeper understanding
of the disease. Our aim for this study was to identify proteins
differentially abundant in the Synovial Fluid from patients suffering
from Rheumatoid Arthritis (RA) or Osteoarthritis (OA) using mass
spectrometry.
Methods: 20 individual samples for each condition were pooled in two
groups with the aim of reducing the contribution of individual extreme
values. Since SF presents a similar dynamic range than serum in terms
of protein concentration, we decided to immuno-deplete the samples to
enrich them in the low-abundant protein fraction. After that, the pooled
samples were subjected to protein size fractioning and in-gel digestion,
followed by Reverse Phase peptide separation in a nano-LC system and
peptide identiﬁcation by MALDI-TOF/TOF. Relative quantitative analysis
and validation of selected proteins was done by Spectral Counting and
Western blot techniques, respectively.
Results: Our results show that in RA there is a relative more abundance
of proteins related to immﬂamation and immune response, such as
major matrix metalloproteinases, MMP-1 and MMP-3, as well as MRP-8,
Calgranulin-A and Plastin-2, all known markers of inﬂammation and
immune response. On the contrary, we found in OA that proteins involved
in the formation and remodelling of the extracelular matrix [ECM],
between them Fibronectin, Kininogen-1, Cartilage Acidic Protein 1
and Cartilage Oligomeric Matrix Protein are relatively more abundant,
suggesting a possible role in the pathological process. Validation by
Western blot of two differentially accumulated proteins, MMP-1 and
Fibronectin, in individual SF samples supports the mass spectrometry
data.
Conclusions: Since SF is in direct contact with the affected tissues –
cartilage, synovial membrane and bone – it results an excellent source
for biomarker discovery. All together, our data show that LC-MALDI-
TOF/TOF is a technique suitable to face the current need of discovering
early indicators in the OA process, since we have demonstrated that
comparative quantitation of two different pathologies affecting the joint,
RA vs OA, yields substantially different protein proﬁles. Also, the relative
abundance of ECM proteins in SF samples from OA patients strongly
supports that enhanced ECM production and turnover by activated
metalloproteases is a central hallmark in the pathogenic process in OA
leading to progressive erosion of structural integrity of the joint and
eventual loss of functional performance.
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TWO NOVEL SUPERSENSITIVE BIOCHEMICAL MARKERS OF
INFLAMMATION, MATRIX METALLOPROTEINASE AND CATHEPSIN
GENERATED FRAGMENTS OF C-REACTIVE PROTEIN
H. Skjot-Arkil1, A-C. Bay-Jensen1, G. Schett2, D.J. Leeming1, M.A. Karsdal1.
1Nordic BioSci. A/S, Herlev, Denmark; 2Univ. of Erlangen-Nuremberg,
Erlangen, Germany
Purpose: Joint degenerative diseases (JDD) are widely affected by
inﬂammation joints. Current markers of inﬂammation, such as C-reactive
protein (CRP), are reﬂecting the production of an acute phase reactant
rather than tissue speciﬁc inﬂammation.
The use of CRP as marker for JDD has not provided the sought accuracy
and speciﬁcity. We hypothesized that local enzymatic activity (e.g. MMPs
and Cathepsins) in the affected tissue, which is associated with extensive
tissue turnover, may cleave the CRP produced in the liver and produce
a more tissue speciﬁc CRP. These cleavage products of CRP may provide
additional information on the systemic inﬂammation compated to that
provided by traditional full length CRP. We investigated whether these
CRP degradation products would provide additional diagnostic value
by measuring two newly developed MMP and cathepsin mediated CRP
fragments in patients with JDD.
Methods: CRP fragments were identiﬁed by mass-spectrometry. Two
fragments were selected as antigens for antibody development, followed
by ELISA development. One assay exclusively identiﬁed a matrix
metalloproteinase (MMP) generated fragment, CRP-MMP, whereas the
other assay identiﬁed a cathepsin generated fragment, CRP-CAT. The
ELISA was characterized and the technical performance was tested and
recorded. Full-length CRP, CRP-MMP and CRP-CAT were measured in
serum samples from 40 patients and 40 sex and age-matched controls.
Results: The accuracy and precision was acceptable with low inter- and
intra-assay variation (<10%), as well as dilution recovery. Full-length CRP
was not elevated in the patients compared to controls, whereas CRP-
MMP was elevated by 25% (p < 0.001) and CRP-CAT by 50% (p < 0.0001).
The AUC of the ROC of CRP-CAT was the highest with 77%.
Conclusions: MMP and cathepsin degraded CRP provided more
discriminative diagnostic potential compared to that of full-length CRP
in this current study. These data suggest that different pools of CRP
may provide insight into the inﬂammation processes in JDD. Further
studies are needed to investigate wether these novel fragments have
more prognostic power compared that of full length CRP.
155
CORRELATION OF KNEE CARTILAGE THICKNESS CHANGE AT 1 YEAR
WITH CLINICAL OUTCOME CHANGES AT 1 AND 3 YEARS: DATA FROM
THE OSTEOARTHRITIS INITIATIVE
R. Buck1, M. Nevitt2, W. Wirth3,4, F. Eckstein3,4. 1StatAnswers Consulting
LLC, Minnetonka, MN, USA; 2Univ. of California and OA Initiative
Coordinating Ctr., San Francisco, CA, USA; 3Paracelsus Med. Univ., Salzburg,
Austria; 4Chondrometrics, Ainring, Germany
Purpose: An important characteristic of any biomarker is that it
be associated with clinical outcomes and ideally be able to predict
future outcomes. Change in knee cartilage thickness is an important
characteristic of osteoarthritis and is believed to impact clinical outcomes
such as pain assessments which are key to disease management. Hence
small short-term changes in knee cartilage thickness may predict changes
in future clinical outcomes. The OAI study provides an opportunity
to examine the relationship between short (1 year) changes in knee
cartilage thickness and concurrent (1 year) or future (3 years) changes
in clinical outcomes.
Methods: Measurements of change in mean subregional cartilage
thickness (DThCtAB) over 12 months were available from coronal FLASH
MR images for one knee of 795 OAI subjects, 185 men and 242 women
from the Progression cohort and 135 men and 233 women from the
Incidence cohort. Subjects were restricted to those that underwent some
change in clinical outcomes. The Progression cohort was split to consider
signal (osteophytes and pain present) and non-signal knees (either
osteophytes or pain not present) separately. See Table for sample sizes.
Baseline and follow-up scans were read in pairs with readers blinded
to visit. Change in ThCtAB was measured in 16 femorotibial subregions
[2]. Linear models considering all subregion DThCtAB were constructed
to predict change in clinical outcomes over 3 years (DOutcome). Clinical
outcomes examined were WOMAC (Total, Pain, Stiffness, Disability) or
KOOS (Pain, Symptom) individual knee scores. Ordered values (OV)
of DThCtAB were also considered as predictors [1]. Ordered values
were considered for medial and lateral subregions separately and
combined (All). Coefﬁcient of determination (%), R2, was used to measure
association between multivariate Predictors and DOutcomes.
Table: The coefﬁcients of determination (%: min, mean, max) across
clinical outcomes for different cohorts
Cohort Interval ThCtAB med+lat OV All OV
Incidence 1 Year (0.0, 1.0, 2.9) (1.3, 3.8, 6.3) (2.3, 7.2, 11.2)
3 Year (0.0, 0.6, 1.8) (1.5, 5.1, 13) (3.0, 5.0, 8.1)
Progression 1 Year (2.9, 4.7, 8.1) (3.1, 5.1, 7.4) (1.9, 3.5, 4.9)
3 Year (3.0, 4.6, 7.0) (4.3, 5.5, 6.3) (1.6, 4.1, 7.4)
Signal knee 1 Year (4.0, 6.0, 9.3) (2.2, 5.0, 7.1) (4.5, 8.1, 12.1)
3 Year (5.5, 8.2, 12.3) (4.9, 7.1, 8.8) (5.0, 7.2, 10.4)
Non-signal 1 Year (4.5, 14.3, 23.1) (20.1, 22.8, 28.7) (9.2, 18.3, 29.4)
3 Year (3.0, 6.5, 10.5) (12.6, 19.9, 24.9) (8.8, 14.8, 28.7)
Results: R2 was relatively consistent across clinical outcomes. R2 was
typically low (<0.07) when predicting DOutcome using all subjects,
Incidence or Progression cohorts. R2 increased when signal and non-
signal knees of Progression cohort are considered separately, particularly
